Riskpilot← Back to searchSign inGet full accessAGC Biologics A/S
A/SActiveCVR 25950941Vandtårnsvej 83Manufacture of pharmaceutical preparations · NACE 2120Est. 20011311 employees
Revenue 2024
DKK 2B
-4% vs 2023
EBITDA margin
0.4%
-98% vs 2023
Equity ratio
16.9%
Financial strength
Net profit 2024
DKK -115M
-147% vs 2023
| Revenue | DKK 2B | -4% |
| EBITDA | DKK 7,5M | -98% |
| Net profit | DKK -115M | -147% |
| Total assets | DKK 3,8B | +5% |
| Equity | DKK 640M | +108% |
| Employees | 1311 | — |
Legal name
AGC Biologics A/S
CVR number
25950941
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
15. marts 2001
Share capital
DKK 42.852.973
Employees
1311 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør, af bestyrelsens formand i forening med 2 bestyrelsesmedlemmer, 2 bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed, som omfatter proces- og teknologiudvikling, kontraktproduktion, konsulent- og andre serviceydelser indenfor det bioteknologiske område samt forskning, udvikling og fremstilling af medicinalprodukter, og dermed forbunden virksomhed.
Address
Vandtårnsvej 83
Phone
+4570209470
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.248 | 311.091 | 320.466 | 521.795 | 643.563 | 692.613 | 996.136 | 1.455.071 | 2.185.033 | 2.517.996 | 2.092.565 | 2.016.194 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 4.227 | 12.194 | 22.308 | 90.977 | 133.215 | 151.388 | 258.766 | 428.560 | 806.122 | 878.238 | 443.827 | 7.513 |
| Depreciation & amort. | -0 | -0 | -0 | -22.560 | -30.455 | -32.050 | -55.311 | -58.061 | -73.078 | -84.775 | -91.613 | -114.539 |
| EBIT | 4.227 | 12.194 | 22.308 | 68.417 | 102.760 | 119.338 | 203.455 | 370.499 | 733.044 | 793.463 | 352.214 | -107.026 |
| Net financials | -4.274 | -9.094 | -13.936 | -13.821 | -7.038 | 4.271 | -5.336 | -13.375 | 1.014 | -24.993 | -36.180 | -88.851 |
| Profit before tax | -47 | 3.100 | 8.373 | 54.596 | 95.722 | 123.609 | 198.119 | 357.124 | 734.058 | 768.469 | 316.034 | -145.332 |
| Tax | 81 | -81 | -0 | -13.625 | 21.194 | 27.442 | 43.791 | 78.586 | 162.323 | 169.520 | 72.165 | -30.327 |
| Net profit | -128 | 3.181 | 8.373 | 68.222 | 74.528 | 96.167 | 154.328 | 278.538 | 571.735 | 598.949 | 243.869 | -115.005 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 311.339 | 346.594 | 404.229 | 580.983 | 501.574 | 634.585 | 1.182.430 | 2.347.541 | 3.140.663 | 3.439.426 | 3.623.676 | 3.788.309 |
| Equity | 136.341 | 139.522 | 147.895 | 216.116 | 290.644 | 316.811 | 215.139 | 339.677 | 633.585 | 661.277 | 307.426 | 640.031 |
| Long-term debt | 25.340 | 154.060 | 155.126 | 32.272 | 29.298 | 37.865 | 249.055 | 656.164 | 605.333 | 817.716 | 1.116.374 | 1.691.327 |
| Short-term debt | 149.658 | 53.013 | 101.208 | 332.595 | 181.632 | 279.909 | 708.893 | 1.332.860 | 1.882.633 | 1.939.308 | 2.180.601 | 1.456.951 |
| Total debt | 174.998 | 207.073 | 256.334 | 364.867 | 210.930 | 317.774 | 967.291 | 2.007.864 | 2.507.078 | 2.778.149 | 3.316.250 | 3.148.278 |
EBITDA margin
0.4%
This company
15.8%
Market median
-97% vs market
20132024
Equity ratio
16.9%
This company
38.2%
Market median
-56% vs market
20132024
Return on equity
-18.0%
This company
18.4%
Market median
-198% vs market
20132024
Net profit margin
-5.7%
This company
8.1%
Market median
-170% vs market
20132024
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20132024
Debt / equity
4.92×
This company
0.62×
Market median
-694% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CJ Management | Management | 2012 | — | — |
KM Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
SJ Management | Management | 2006 | — | — |
PE Management | Management | 2012 | — | — |
AV Management | Management | 2002 | — | — |
DR Management | Management | 2012 | — | — |
GF Management | Management | 2012 | — | — |
AC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
GF Audit | Audit | 2001 | — | — |
JZ Deputy | Deputy | 2005 | — | — |
JM Management | Management | 2012 | — | — |
CH Management | Management | 2006 | — | — |
CJ Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
LF Management | Management | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2001 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2002 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2002 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2002 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2006 | — | — | |
| Chairman | 2001 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2008 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 2001 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2017 | |
| Individual | 5.0% | 0.0% | 2017 | |
| Individual | 100.0% | 100.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AGC Biologics A/S 
AGC Biologics Copenhagen ApSBoard members of AGC Biologics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claès Johan Robert Glassell | Management | 0 companies |
| Kasper Møller | Chief Executive Officer | 0 companies |
| Stephen John Bellis | Management | 0 companies |
| Patricio Ezequiel Massera | Management | 0 companies |
| Anders Vinther | Management | 0 companies |
| Douglas Robert Sanders | Management | 0 companies |
| Gustavo Fabio Mahler | Management | 0 companies |
| Andrea Celia Porchia | Chief Executive Officer | 0 companies |
| Gert Fisker Tomczyk | Audit | 0 companies |
| Jesper Zeuthen | Deputy | 0 companies |
| Jens Malta Velling | Management | 0 companies |
| Christian Henrik Tange | Management | 0 companies |
| Claes Johan Robert Glassell | Chief Executive Officer | 0 companies |
| Lone Fønss Schrøder | Management | 0 companies |
| Thomas Léon Yves Marie Balland | Board of Directors | 0 companies |
| Alberto Santagostino | Board of Directors | 0 companies |
| Mette Kirstine Agger | Board of Directors | 0 companies |
| Mads Aage Laustsen | Chairman | 0 companies |
| Björn Carl-Johan Dellgren | Board of Directors | 0 companies |
| Yuichiro Tashiro | Board of Directors | 0 companies |
| Ikuo Matsukura | Board of Directors | 0 companies |
| Yuichiro Tashiro | Board of Directors | 0 companies |
| Tomoko Miyagawa | Board of Directors | 0 companies |
| Juha Aimo Koivurinta | Board of Directors | 0 companies |
| Hiroshi Nishimura | Board of Directors | 0 companies |
| Akira Nakamura | Board of Directors | 0 companies |
| David Kauffmann | Chairman | 0 companies |
| Masahiko Fukamachi | Board of Directors | 0 companies |
| Hideyuki Kurata | Chairman | 0 companies |
| Thomas Tscherning | Board of Directors | 0 companies |
| Hideaki Kan | Board of Directors | 0 companies |
| Noriyuki Komuro | Chairman | 0 companies |
| William John Henry | Board of Directors | 0 companies |
| Morten Boje Munk | Chairman | 0 companies |
| Lars Hallgren | Board of Directors | 0 companies |
| Mai Iwaya | Board of Directors | 0 companies |
| Tadashi Murano | Chairman | 0 companies |
| Paul Howard Michael Toon | Board of Directors | 0 companies |
| Yukiteru Nakashita | Board of Directors | 0 companies |
| Stephen Andrew Lehman | Board of Directors | 0 companies |
| Peter Klarskov Vilby | Chairman | 0 companies |
| Frank Harder | Board of Directors | 0 companies |
| Jesper Bramming | Chairman | 0 companies |
| Patricio Ezequiel Massera | Board of Directors | 0 companies |